[email protected]
+1 718 874 1545 (International)
+91 78878 22626 (Asia)
Search...
All Reports
All Sectors
Who Trust Us
Home ➤ Life Science ➤ Healthcare ➤ Stem Cell Therapy Market
Global Stem Cell Therapy Market By Cell Source (Ipscs, Ppscs,
Neural), By Type (Allogenic And Autologous), By Application
(Cardiovascular, Diabetes), By End User (Hospitals & Clinics,
Academic & Research Centers) By Region And Companies Industry Segment Outlook, Market Assessment, Competition
Scenario, Trends, And Forecast; 2023-2032
Published date: Nov
2023
Overview
Report ID:
12272
Table of Contents
Number of Pages:
329
Inquiry Before Buying
Mention interested
topics/company profiles.
Format:
Major Market Players
Enter Name
Request a Free Sample
Enter Email ID
-Select CountryEnter Phone Number
Quick Navigation
Enter Company Name
Report Overview
Submit
The Global Stem Cell Therapy Market Size was valued at USD 11.1 billion in
2022 and will expand to USD 44.5 billion in 2032 with a CAGR of 15.3% in the
forecast period 2023-2032.
Stem cell therapy is used for stem cell transplants in which stem cells are
replaced by chemotherapy or act as a donor’s immune system to fight
diseases related to blood or cancer, such as multiple myeloma,
Report ID
lymphoma, neuroblastoma, and leukemia. Cell therapy includes types like
12272
mesenchymal stem cells (MSCs), skin stem cells (SSCs), hematopoietic
Published Date
stem cells (HSCs), and neural stem cells (NSCs). The cost of stem cell
Nov 2023
therapy procedures can cost between USD 5,000 and USD 50,000.
Rating
★★★★★ (45)
The market for stem cell therapy can be increased by boosting funding to
stem cell research, increasing clinical trials linked to stem cell therapy, and
boosting the number of production facilities for cell therapy. During the
pandemic, many cell therapies clinical trials have been done due to the
add_shopping_cart
Buy Now
advantages of stem cell therapies.
Trusted by more than 17382
organizations globally
*Actual Numbers Might Vary In The Final Report
Key Takeaways
The worldwide stem cell therapy market size was USD 11.1 billion in
2022.
This market is expected to reach USD 44.5 billion by 2032.
The stem cell therapy market is growing at a CAGR of 15.3%.
The cost of stem cell therapy can range from USD 5,000 to USD
50,000.
Allogenic therapy had a 74% market share in 2022.
Hospitals and clinics were the largest end-users, with a 28% market
share.
North America dominated the market with a 35% revenue share in
2022.
Europe held a 29% revenue share in 2022.
Investments in stem cell research and clinical trials have boosted the
market.
Increasing awareness of stem cell therapy’s importance is driving
growth.
Stem cell banking is on the rise due to public awareness.
The global cancer burden is increasing, driving the need for stem cell
transplants.
Ethical issues and regulatory concerns can limit the growth of stem
cell research.
By Cell Source Analysis
The Dipose Tissue Segment Segment Accounted for The Largest Market
Share In Cell Source Type Owing To its Used In Adipose Tissue Or Fatty
Tissue As A Specialized Connective Tissue
Based on cell source types, the global stem cell therapy market share is
segmented into IPSCs, PPSCs, neural, embryo/cord, adipose tissue, and
bone marrow. Among these cell sources, the largest market share was
occupied by the adipose tissue segment with a 34% market share in 2022.
Because these cell source segments are used in adipose tissue or fatty
tissue is a specialized connective tissue consisting of lipid-rich cells called
adipocytes found mainly under the skin and also in deposits between the
muscles, around the heart, in the intestines, membrane folds of the
intestine, and elsewhere.
By Type Analysis
The Allogenic Segment Accounted for the Largest Market Share In The
Type Owing To Their Prevalence Of Cancer And Related Diseases Among
Individuals
Based on the type, the global stem cell therapy market share is
segregated into allogenic stem cell therapy and autologous stem cell
therapy. Among these types, the largest market share was occupied by
the allogenic segment with a 74% market share in 2022. Because global
consumption of allogeneic stem grafts is growing owing to the increasing
incidence of cancer and other related disorders.
According to the WHO, children between the ages of 0 to 19 are diagnosed
with almost 300K new cases of cancer annually. In 2022, there will be 21
million new cases of cancer, according to estimates. This puts a strain on
the global healthcare system and increases the demand for cancer
treatments that are efficient anywhere in the world.
By Application Type Analysis
The Diabetes Segment Accounted for The Largest Market Share In The
Application Type Owing To The Large Number Of Individual
Based on application type, the global stem cell therapy market is
segmented into cardiovascular, diabetes, cancer, musculoskeletal
disorders, and gastrointestinal diseases. Among these types, the largest
market share was occupied by the diabetes segment with a 28% market
share in 2022.
Because the WHO estimates that 450 million people worldwide have
diabetes. Diabetes is more common in nations with low and medium
incomes. Diabetes, also referred to as diabetes mellitus, is just a metabolic
disorder that develops whenever blood glucose levels are too high. Over
time, this illness causes major harm to the kidneys, eyes, blood vessels,
heart, and eyes.
By End User Type Analysis
The Hospitals & Clinics Segment Accounted for The Largest Market Share
In The End User Type Owing To Its Increased Frequency Of Skin Conditions
Like Acne
Based on end-user type, the global stem cell therapy market is segmented
into hospitals & clinics, academic & research centers, ambulatory surgical
centers, and other end users. Among these types, the largest market share
was occupied by the hospitals & clinics segment with a 28% market share
in 2022 because, the increasing frequency of skin conditions like acne.
Key Market Segments
By Cell Source
IPSCS
PPSCS
Neural
Embryo/cord
Adipose Tissue
Bone Marrow
By Type
Allogenic
Autologous
By Application
Cardiovascular
Diabetes
Cancer
Musculoskeletal Disorders
Gastrointestinal Diseases
By End User
Hospitals & Clinics
Academic & Research Centers
Ambulatory Surgical Centers
Other End Users
Drivers
Increasing Rate of Chronic Diseases
The need for efficient treatment is being caused by the increasing rate of
chronic diseases. Along with the ongoing COVID-19 pandemic, chronic
diseases like heart disease, cancer, stroke, respiratory illnesses,
neurological disorders, and cardiovascular disorders place a significant
strain on society.
According to the Centers for Disease Control (CDC), four out of ten adults
in 2019 have more than two chronic diseases, and six out of ten adults
have chronic diseases. The data shows how diseases are becoming more
prevalent and how well they are being managed. Clinical trials are
anticipated to increase the demand of stem cells in the forecast period.
Restraints
Expansion of Stem Cell-Based Therapy Is Constrained By Ethical Issues
Even though stem cell research holds immense potential for the medical
sector, its expansion is constrained by ethical issues from regulatory body.
The destruction of the human embryonic stem cell is one of the main
obstacles that might have hindered the advancement of stem cell
research.
Opportunity
Demand for Stem Cells Banking Has Increased For Development Activity
The demand for the banking of stem cells has increased as the number of
chronic disorders and life-challenging genetic abnormalities have
increased. A growing number of firms have entered the stem cell banking
sector as a result of rising public awareness of stem cell therapy.
Genetically programmed adult stem cells using embryonic stem cell
known as pluripotent stem cells to increase sales and market for stem cell
therapy.
Regional Analysis
North America Dominated the Global Stem Cell Therapy Market
In 2022, North America held a 35% share of the global stem cell therapy
market. The region benefits due to the most recent cutting-edge
technologies, economic expansion, and significant governmental & private
investment. The availability of the latest research infrastructure increased
R&D efforts to create therapeutic choices for chronic diseases, and simple
review processes for clinical trials are further market-driving elements in
the area.
Major research organizations and market suppliers headquartered here
receive significant funding from the United States. The numerous projects
in the region’s pipeline are boosting consumer demand.
Asia-Pacific is expanding at the fastest rate & Europe owns the secondlargest share
Due to a rise in the demand for stem cell therapy and an increased
prevalence of chronic and neurological illnesses, Europe owns the secondlargest share of the market.
The cell therapy market growth in Asia-Pacific, it is expanding at the
fastest growth rate because of its rapid growth and the arrival of several
companies. Additionally, the Asia Pacific region’s growing use of stem cell
therapy treatments and rising cancer prevalence are projected to fuel
market expansion.
Key Regions
North America
The US
Canada
Mexico
Eastern Europe
Russia
Poland
The Czech Republic
Greece
Rest of Eastern Europe
Western Europe
Germany
France
The UK
Spain
Italy
Portugal
Ireland
Austria
Switzerland
Benelux
Nordic
Rest of Western Europe
APAC
China
Japan
South Korea
India
Australia & New Zealand
Indonesia
Malaysia
Philippines
Singapore
Thailand
Vietnam
Rest of APAC
Latin America
Brazil
Colombia
Chile
Argentina
Costa Rica
Rest of Latin America
Middle East & Africa
Algeria
Egypt
Israel
Kuwait
Nigeria
Saudi Arabia
South Africa
Turkey
United Arab Emirates
Rest of MEA
Key Players Analysis
To increase their market position, Using Methods Such as Alliances,
Mergers and acquisitions, Geographic Coverage, And Strategic
Partnerships. For example, Celularity Inc. and GX Acquisition Corp. signed a
merger agreement to speed up the development & production of fresh
and novel allogeneic cell therapies like CAR T therapies obtained from the
genetically engineered natural killer cell therapies and postpartum
placenta.
Market Key Players
With the presence of many local and regional players, the market for
companion diagnostics is fragmented. Market players are subject to
intense competition from prominent players, particularly those with strong
brand recognition and high distribution networks. To stay on top of the
market, companies have gained various expansion strategies such as
partnerships and product launches.
The following are some of the key market players in the global stem cell
therapy industry:
Seraxis, Inc. (Germany)
Fresenius Medical Care AG & Co. KGaA (Germany)
Generex Biotechnology (Canada)
Medipost Co., Ltd (South Korea)
Pharmicell Co., Ltd (South Korea)
JCR Pharmaceuticals Co., (Japan)
Novadip Biosciences(Belgium)
Anterogen Co., Ltd (South Korea)
StemCell Technologies Inc. (Canada)
Sernava Corp (Canada)
NextCell Pharma AB (US)
ViaCyte, Inc. (US)
Vertex Pharmaceuticals (US)
NuVasive, Inc. (US)
Novo Nordisk A/S (Denmark)
Kadimastem (Israel)
Betalin Therapeutics Ltd (Israel)
Other Key Players
Recent Developments
In February 2022, The Chinese patent office granted Cynata
Therapies firm, a patent for its unique “MSC” technology or
CymerusTM mesenchymal stem cell. The patent was granted to a
company by the close of May 2022 and is valid till March 2037.
In February 2022, A deal with eQcell has been announced by Likarda
(LLC) creating cutting-edge delivery technologies. According to the
terms of the agreement, the specialized hydrogel encapsulating
product for their equine multipotent stromal cells may be licensed
globally.
January 2022, A well-known biotech business, Gamida Cell, has
declared that it will begin a FDA filing for the blood cancer drug
omidubicel. However, in order to succeed, it needs a little assistance
from a strategic partner and a staff reduction.
Report Scope
Report Features
Description
Market Value (2022)
USD 11.1 Billion
Forecast Revenue
USD 44.5 Billion
(2032)
CAGR (2023-2032)
15.3%
Base Year for
2022
Estimation
Historic Period
2016-2021
Forecast Period
2023-2032
Report Features
Description
Report Coverage
Revenue Forecast, Market Dynamics, COVID-19
Impact, Competitive Landscape, Recent
Developments
Segments Covered
By Cell Source (IPSCS, PPSCS, Neural, Embryo/Cord,
Adipose Tissue, And Bone Marrow); By Type
(Allogenic And Autologous); By Application
(Cardiovascular, Diabetes, Cancer, Musculoskeletal
Disorders, And Gastrointestinal Diseases); By End
User (Hospitals & Clinics, Academic & Research
Centers, Ambulatory Surgical Centers, And Other End
Users)
Regional Analysis
North America – The US, Canada, & Mexico; Western
Europe – Germany, France, The UK, Spain, Italy,
Portugal, Ireland, Austria, Switzerland, Benelux,
Nordic, & Rest of Western Europe; Eastern Europe –
Russia, Poland, The Czech Republic, Greece, & Rest of
Eastern Europe; APAC – China, Japan, South Korea,
India, Australia & New Zealand, Indonesia, Malaysia,
Philippines, Singapore, Thailand, Vietnam, & Rest of
APAC; Latin America – Brazil, Colombia, Chile,
Argentina, Costa Rica, & Rest of Latin America;
Middle East & Africa – Algeria, Egypt, Israel, Kuwait,
Nigeria, Saudi Arabia, South Africa, Turkey, United
Arab Emirates, & Rest of MEA
Competitive
Seraxis, Inc. (Germany), Fresenius Medical Care AG &
Landscape
Co. KGaA (Germany), Generex Biotechnology
(Canada), Medipost Co., Ltd (South Korea),
Pharmicell Co., Ltd (South Korea), JCR
Pharmaceuticals Co.,(Japan), Novadip
Biosciences(Belgium), Anterogen Co., Ltd (South
Korea), StemCell Technologies Inc. (Canada),
Sernava Corp (Canada), NextCell Pharma AB (US),
ViaCyte, Inc. (US), Vertex Pharmaceuticals (US),
NuVasive, Inc. (US), Novo Nordisk A/S
(Denmark),Kadimastem (Israel), Betalin
Therapeutics Ltd (Israel), and Other Key Players
Customization Scope
Customization for segments, region/country-level
will be provided. Moreover, additional customization
can be done based on the requirements.
Purchase Options
We have three licenses to opt for: Single User
License, Multi-User License (Up to 5 Users),
Corporate Use License (Unlimited User and Printable
PDF)
Frequently Asked Questions (FAQ)
How much is the Global Stem Cell Therapy Market worth?
Global Stem Cell Therapy Market market size is Expected to
Reach USD 44.5 Bn by 2032.
What was the Market Segmentation of the Stem Cell Therapy
Market?
By Cell Source (IPSCS, PPSCS, Neural, Embryo/Cord, Adipose
Tissue, And Bone Marrow); By Type (Allogenic And Autologous);
By Application (Cardiovascular, Diabetes, Cancer,
Musculoskeletal Disorders, And Gastrointestinal Diseases); By End
User (Hospitals & Clinics, Academic & Research Centers,
Ambulatory Surgical Centers, And Other End Users)
What is the CAGR of Stem Cell Therapy Market?
The Stem Cell Therapy Marketis growing at a CAGR of 15.3%
during the forecast period 2023 to 2033.
Who are the major players operating in the Stem Cell Therapy
Market?
Seraxis, Inc. (Germany), Fresenius Medical Care AG & Co. KGaA
(Germany), Generex Biotechnology (Canada), Medipost Co., Ltd
(South Korea), Pharmicell Co., Ltd (South Korea), JCR
Pharmaceuticals Co.,(Japan), Novadip Biosciences(Belgium),
Anterogen Co., Ltd (South Korea), StemCell Technologies Inc.
(Canada), Sernava Corp (Canada), NextCell Pharma AB (US),
ViaCyte, Inc. (US), Vertex Pharmaceuticals (US), NuVasive, Inc.
(US), Novo Nordisk A/S (Denmark),Kadimastem (Israel), Betalin
Therapeutics Ltd (Israel), and Other Key Players
Which region will lead the Global Stem Cell Therapy Market?
North America is estimated to be the fastest-growing region
during the forthcoming years.
Stem Cell Therapy Market
Published date: Nov 2023
add_shopping_cart
get_app
Buy Now
Download Sample
Related Reports
Stem Cell Market
Mesenchymal Stem Cells Market
Cell Therapy Market
Adhesion Barrier Market
Medical Cyclotron Market
Antibody Production Market
Our Clients
SINGLE USER
MULTI USER
CORPORATE USER
$6,000
$8,000
$10,000
$3,999
$5,999
$6,999
USD / PER UNIT
USD / PER UNIT
USD / PER UNIT
SAVE 24%
SAVE 28%
SAVE 32%
No
up to 10 hrs work
up to 30 hrs work
1 User
2-5 User
Unlimited
up to 20 hrs
up to 40 hrs
up to 50 hrs
Up to 20% off on next
purchase
Up to 25% off on next
purchase
Up to 30% off on next
purchase
Buy Now ($ 3,999)
Buy Now ($ 5,999)
Buy Now ($ 6,999)
e-Access
Report Library Access
Data Set (Excel)
Print
Company Profile Library
Access
Interactive Dashboard
Free Custumization
Accessibility
Analyst Support
Benefit
location_on
phone
phone
email
420 Lexington Avenue, Suite 300 New York City, NY 10170,
United States
+1 718 874 1545 (International)
+91 78878 22626 (Asia)
[email protected]
Find Help
Contact Us
How to Order
Legal
Privacy Policy
Refund Policy
Frequently Asked Questions
Terms and Conditions
Explore
About Us
All Reports
All Sectors
Infographics
Statistics and Facts
Companies
Secured Payment Options
© 2025 Market.Us. All Rights Reserved.